Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ran Nussbaum Insider Profile
11 Followers
Ran Nussbaum, Director at Kite Pharma Inc, holds 1.44M shares in Urogen Pharma (Ticker: URGN), holds 7.80M shares in Eloxx Pharmaceuticals (Ticker: ELOX), holds 1.23M shares in Keros Therapeutics (Ticker: KROS). Most recently, Ran Nussbaum Bought ― shares of Urogen Pharma on Feb 28, 2023 for an estimated value of 11.05K.
Profitable Transactions
7 out of 14 Profitable Transactions
Average Return
+25.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Ran Nussbaum holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Apr 13, 2020 - Apr 13, 2021
Return:+175.70%
The most profitable trade made by Ran Nussbaum
Ran Nussbaum's Trading History
Kite Pharma Inc
Oct 05, 2017
―
Uninformative Sell
―
$0.00
Arqule
Jan 16, 2020
―
Uninformative Sell
174.90M
$0.00
Eloxx Pharmaceuticals
May 17, 2021
Director
Informative Buy
8.00M
$7.34M
Urogen Pharma
Feb 28, 2023
Director
Informative Buy
11.05K
$20.49M
Keros Therapeutics
Nov 19, 2020
Director, Ten Percent Owner
Informative Buy
3.00M
$72.30M
Prevail Therapeutics
―
―
―
―
List of latest transactions for each holding click on a transaction to see Ran Nussbaum's performance on stock
You May Also Like
Ran Nussbaum insider profile FAQ
What is the percentage of profitable transactions made by Ran Nussbaum?
The percentage of profitable transactions made by Ran Nussbaum is 50%.
What is the average return per transaction made by Ran Nussbaum?
The average return per transaction made by Ran Nussbaum is 25.00%.
What stocks does Ran Nussbaum hold?
Ran Nussbaum holds: KITE, ARQL, ELOX, URGN, KROS, PRVL stocks.
What was Ran Nussbaum’s latest transaction?
Ran Nussbaum latest transaction was an Informative Buy of $11.05K.
What was Ran Nussbaum's most profitable transaction?
Ran Nussbaum’s most profitable transaction was an Informative Buy of KROS stock on April 13, 2020. The return on the trade was 175.70%.
What is Ran Nussbaum's role in Kite Pharma Inc?
Ran Nussbaum's role in Kite Pharma Inc is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.